E
LLYStocks
Eli Lilly and Company
1,371.03+89.94 (+7.02%)
Market closed · Oct 29, 2026, 07:44 PM · delayed 15 min
1,371.03+89.94 (+7.02%)
| Breakdown | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 | Q1 2024 Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $42.77B | $19.8B | $45.89B | $28.29B | $12.73B | $31.51B | $20.07B | $8.77B |
| Cost of Revenue | $6.85B | $3.58B | $7.68B | $4.67B | $2.23B | $6.01B | $3.84B | $1.67B |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Expenses | — | — | — | — | — | — | — | — |
| R&D | — | — | — | — | — | — | — | — |
| Selling, General & Administrative | $6.36B | $2.93B | $7.96B | $5.22B | $2.47B | $6.17B | $4.07B | $1.95B |
| Operating Income | — | — | — | — | — | — | — | — |
| Pretax Income | $18.1B | $8.85B | $17.46B | $10.23B | $3.46B | $7.64B | $6.05B | $2.54B |
| Income Tax | $3.61B | $1.45B | $3.46B | $1.81B | $697M | $1.46B | $843.4M | $293.2M |
| Net Income | $14.49B | $7.4B | $14B | $8.42B | $2.76B | $6.18B | $5.21B | $2.24B |
| EPS (Basic) | $16.22 | $8.27 | $15.60 | $9.37 | $3.07 | $6.86 | $5.78 | $2.49 |
| EPS (Diluted) | $16.19 | $8.26 | $15.56 | $9.35 | $3.06 | $6.83 | $5.76 | $2.48 |
| company.financials.row.grossMargin | — | — | — | — | — | — | — | — |
| company.financials.row.operatingMargin | — | — | — | — | — | — | — | — |
| company.financials.row.netMargin | 0.34 | 0.37 | 0.31 | 0.30 | 0.22 | 0.20 | 0.26 | 0.26 |
Negative figures shown in red. Scroll the table sideways for older periods.
SEC EDGAR